Considerations on COM(2017)758 - Subjecting the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
| dossier | COM(2017)758 - Subjecting the new psychoactive substance ... |
|---|---|
| document | COM(2017)758  |
| date | December 18, 2017 |
(2) AB-CHMINACA is a synthetic cannabinoid. It shows similar effects to THC, which is responsible for the major psychoactive effects of cannabis, but with additional life-threatening toxicity. The high potency of AB-CHMINACA and the large and variable content of the substance in smoking mixtures constitute a high risk of poisoning.
(3) AB-CHMINACA has been available in the Union since at least April 2014 and has been detected in 24 Member States. Due to the nature of AB-CHMINACA, detections are likely to be under-reported since the substance is not routinely screened for. In most cases, the substance was seized as herbal/plant material, but it was also seized in powder form and to a lesser extent in other physical forms (e.g. as liquid and as blotter). More than 4600 seizures have been made within the European Union.
(4) 31 deaths associated with AB-CHMINACA have been reported by six Member States. In at least nine deaths AB-CHMINACA was the cause of death or is likely to have contributed to the death. In addition, seven acute non-fatal intoxications associated with AB-CHMINACA were reported by four Member States. Due to the nature of AB-CHMINACA, both non-fatal intoxications and deaths are likely to be under-detected and under-reported.
(5) There is no specific information on the involvement of organised crime in the manufacture, distribution (trafficking) and supply of AB-CHMINACA within the Union. The available data suggest that AB-CHMINACA is produced by chemical companies based in China.
(6) AB-CHMINACA is typically sold in small and wholesale amounts branded as 'legal-high' smoking mixtures and as powder in head shops as well as on the internet as 'legal' replacements for cannabis. It may also be sold directly on the illicit drug market. Because these products rarely state the ingredients, most users will be unaware that they are using synthetic cannabinoids in general and AB-CHMINACA in particular.
(7) AB-CHMINACA has no recognised human or veterinary medical use in the Union nor, it appears, elsewhere. There are no indications that AB-CHMINACA may be used for any other purpose aside from as an analytical reference standard and in scientific research.
(8) The risk assessment report reveals that many of the questions related to AB-CHMINACA that are posed by the lack of data on the risks to individual health, risks to public health, and social risks could be answered through further research. However, the available evidence and information on the health and social risks that the substance poses provides sufficient ground for subjecting AB-CHMINACA to control measures across the Union.
(9) AB-CHMINACA is not listed for control under the 1961 United Nations Single Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances. The substance is currently under assessment by the United Nations system and has been reviewed at the 39th meeting of the WHO Expert Committee on Drug Dependence (ECDD) held from 6 to 10 November 2017 in Geneva. This does not preclude the Union taking a decision to subject the substance to control measures.
(10) Given that 18 Member States control AB-CHMINACA under national drug control legislation and three Member States control AB-CHMINACA under other legislation, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect from the risks that its availability and use can pose.
(11) Decision 2005/387/JHA confers implementing powers upon the Council with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union. As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to subject AB-CHMINACA to control measures across the Union.
(12) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision.
(13) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision.
(14) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption and application of this Decision and is not bound by it or subject to its application.